inotuzumab,blinatumomab
pfizer,ucb,amgen,astellas
['inotuzumab', 'leukemia', 'blinatumomab', 'leusm']
congress #asco22 | delivers results from a phase ii study of mini-hyper cvd + inotuzumab ozogamicin +/- blinatumomab in pts 60 years with nd ph-ve b-all. n=80. 99% responded, 89% cr. 80% pts were mrd-ve after 1 cycle &amp; 94% overall. #leusm #leukemia 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm